These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1503357)

  • 1. The cost effectiveness of cervical cancer screening.
    Miller AB
    Ann Intern Med; 1992 Sep; 117(6):529-30. PubMed ID: 1503357
    [No Abstract]   [Full Text] [Related]  

  • 2. [Costs and problems in cervix cancer screening are considerably underestimated].
    Bistoletti P
    Lakartidningen; 2000 Aug; 97(32-33):3506-8. PubMed ID: 11037597
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].
    Castronovo V; Foidart JM; Boniver J
    Rev Med Liege; 1998 May; 53(5):305-7. PubMed ID: 9689888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Costs and effects of alternative screening programs against cervical cancer].
    Gyrd-Hansen D; Hølund B; Andersen P
    Ugeskr Laeger; 1996 Aug; 158(35):4912-5. PubMed ID: 8801698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-benefit of expanding cervical cancer screening].
    Deng J; Tan H; Yang T; Huang X; Zhou S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 May; 35(5):470-5. PubMed ID: 20543471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for cervical cancer in the era of the HPV vaccine--the urgent need for both new screening guidelines and new biomarkers.
    Kiviat NB; Hawes SE; Feng Q
    J Natl Cancer Inst; 2008 Mar; 100(5):290-1. PubMed ID: 18314471
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of cervical-cancer screening in developing countries.
    Suba EJ; Frable WJ; Raab SS
    N Engl J Med; 2006 Apr; 354(14):1535-6; author reply 1535-6. PubMed ID: 16598056
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effective analysis of mass screening for cervical cancer in Japan.
    Matsunaga G; Tsuji I; Sato S; Fukao A; Hisamichi S; Yajima A
    J Epidemiol; 1997 Sep; 7(3):135-41. PubMed ID: 9337511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination.
    Starkie Camejo H; Li X; Van Kriekinge G
    Public Health; 2015 Jul; 129(7):989-92. PubMed ID: 25834927
    [No Abstract]   [Full Text] [Related]  

  • 10. [Outcome and future of mass screening for uterine cervical cancer].
    Noda K; Tejima K
    Gan No Rinsho; 1983 May; 29(6):483-7. PubMed ID: 6410103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective policies for cervical cancer screening. An international review.
    Fahs MC; Plichta SB; Mandelblatt JS
    Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-benefit considerations in screening for cervical cancer].
    Pedersen K
    Tidsskr Nor Laegeforen; 2015 Jun; 135(11):1022-3. PubMed ID: 26080774
    [No Abstract]   [Full Text] [Related]  

  • 13. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
    Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disputable and unsolved aspects of mass screening].
    Krivoruchko ZA; Rafaliuk NIa; Shuster LA
    Sov Zdravookhr; 1991; (8):48-51. PubMed ID: 1962240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Health economics analysis of cervical cancer screening].
    Boncz I; Sebestyén A; Pál M; Sándor J; Ember I
    Orv Hetil; 2003 Apr; 144(15):713-7. PubMed ID: 12774432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical inquiries. Should we discontinue Pap smear screening in women aged>65 years?
    Curran DR; Stigleman S; Neher JO
    J Fam Pract; 2004 Apr; 53(4):308-10. PubMed ID: 15068776
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness studies on cervical cancer.
    Brown AD; Raab SS; Suba EJ; Wright RG;
    Acta Cytol; 2001; 45(4):509-14. PubMed ID: 11480710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention.
    Raab SS; Zaleski MS; Silverman JF
    Am J Clin Pathol; 1999 Feb; 111(2):259-66. PubMed ID: 9930150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.